Skip to main content

Table 2 Change in primary and secondary outcomes between baseline and 12 months.

From: Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial

  Podiatry care (n = 16) No podiatry care (n = 18)   
Outcome Change BL-12M Change BL-12M Difference (95% CI)* p value
LFISIF (0–21) 0 (-3,1) 1 (0,3) 2 (0 to 4) 0.035
LFISAP (0–30) 0 (-4,2) 0 (-2,1) 0 (-2 to 3) 0.971
DAS (0–10) 0.2 (0,0.5) 0 (0,0.8) 0 (-0.4 to 0.4) 0.791
HAQ (0–3) 0 (-0.03,0) 0 (0,0.25) 0 (-0.12 to 0.33) 0.303
Walking speed (m/s) 0.01 (-0.01,0.07) -0.02 (-0.20,0.02) 0 (-0.1 to 0) 0.411
  1. LFIS, Leeds Foot Impairment Score (IF, Impairment/footwear subscale, AP, Activity limitation/participation restriction subscale); DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; BL-12M, change in score between baseline and 12 months; CI, confidence interval. Values for the change in score from BL-12M are presented as the median (inter-quartile range). The between group difference in change scores was based on the Hodges-Lehman estimate of the median difference with 95% confidence interval based on a two-sided Mann-Whitney U-test.